Key result
SGLT2 inhibitors provide consistent reductions in heart failure hospitalizations and kidney disease progression.
Why the study?
SGLT2 inhibitors have shown cardiovascular and renoprotective benefits in patients with and without diabetes, but a comprehensive summary of current evidence is needed.
Answers are grounded in this paper and cite their sources.
Supports SGLT2 inhibitor use in T2DM, CKD, and HF; confirms class effects across major RCTs.
Sodium-glucose transport protein 2 inhibitors, commonly referred to as SGLT2i, are a group of prescription pharmaceuticals that are approved by the United States Food and Drug Administration for use with diet and exercise to lower blood glucose in adults with type 2 diabetes. Diabetes is a well-recognized major contributor to cardiovascular and renal disease burden. In addition to blood glucose control, SGLT2i have been shown to provide significant cardiovascular and renoprotective benefits in patients with and without diabetes. In this review, we describe current evidence related to the renal and cardiovascular benefits of using SGLT2i.
No takes yet. Share an insight, caveat, or question.
Kansara et al. (2022) conducted a review in Chronic Kidney Disease and Heart Disease. SGLT2 inhibitors vs. Placebo or standard care was evaluated. SGLT2 inhibitors provide significant cardiovascular and renoprotective benefits, demonstrating a uniform reduction in hospitalization for heart failure and progression of kidney disease.
Synapse has enriched 10 related papers. Consider them for comparative context: